ZYNYZ® is marketed by Incyte in the United States. In 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab. ZYNYZ® is a ...

At the low end, the drugs include $119,000 a year to treat certain rare genetic disorders. At the high end: a gene therapy ...

Detailed price information for Ensysce Biosciences Inc (ENSC-Q) from The Globe and Mail including charting and trades.